Axalbion has synthesized and examined new TRPM8 agonists, identifying its lead candidate AX-8
Axalbion is a clinical-stage pharmaceutical company developing TRPM8 agonists for the treatment of chronic cough and dry eyes, two chronic, common and debilitating disorders, with limited treatment options.
Our molecule AX-8 have a rapid onset of action and offer innovative topical treatment opportunities by normalizing abnormal cough and lacrimation reflexes and by decreasing sensory discomfort.
Our lead compound AX-8 is at the clinical stage of development for chronic cough.
